NMS-873 (Synonyms: VCP Inhibitor III) |
カタログ番号GC17250 |
NMS-873 は、IC50 値が 30 nM の強力な選択的アロステリック VCP/p97 阻害剤です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1418013-75-8
Sample solution is provided at 25 µL, 10mM.
NMS-873 is a selective inhibitor of VCP with IC50 value of 30nM [1].
NMS-873 is the most potent and specific VCP inhibitor. It shows similar potency against both wild-type VCP and VCPC522T without affecting the oligomeric state of VCP. NMS-873 is selective against all of the AAA ATPases, HSP90 or some other kinases. The inhibition effect of NMS-873 is potent and somehow selective in a panel of tumor cell lines when its concentration ranges from 0.08μM to 2μM. NMS-873 suppresses cell proliferation in HCT-116 cell line through inducing accumulation of poly-Ub proteins and stabilization of cyclin E and Mcl-1 dose-dependently. Additionally, NMS-873 causes distribution of HCT116 cells, leading a dose and time-dependent increase in the G2 population and in the sub-G1 fraction. Further, NMS-873 shows cell killing activity in hematological tumors as well as a wide variety of solid tumors with IC50 range between 0.08μM and 2μM [1].
References:
[1] Magnaghi P, D'Alessio R, Valsasina B, Avanzi N, Rizzi S, Asa D, Gasparri F, Cozzi L, Cucchi U, Orrenius C, Polucci P, Ballinari D, Perrera C, Leone A, Cervi G, Casale E, Xiao Y, Wong C, Anderson DJ, Galvani A, Donati D, O'Brien T, Jackson PK, Isacchi A. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol. 2013 Sep;9(9):548-56. doi: 10.1038/nchembio.1313. Epub 2013 Jul 28.
Kinase experiment [1]: | |
Biochemical assay development and HTS |
The ATPase activity and the kinetic parameters of recombinant wild-type VCP and its mutants were evaluated by monitoring ADP formation in the reaction, using a modified NADH-coupled assay. As ADP and NADH are ATP-competitive inhibitors of VCP ATPase activity, the standard protocol for the NADH-coupled assay was modified into a two-step procedure. In the first part, an ATP-regenerating system (40 U/ml pyruvate kinase and 3 mM phosphoenolpyruvate) recycles the ADP produced by VCP activity, keeps the substrate concentration constant (thus preventing product inhibition) and accumulates a stoichiometric amount of pyruvate. In the second part, the VCP enzymatic reaction is quenched with 30 mM EDTA and 250 μM NADH and stoichiometrically oxidized by 40 U/ml lactic dehydrogenase to reduce accumulated pyruvate. The decrease of NADH concentration was measured at 340 nm using a Tecan Safire 2 reader plate. The assay was performed in 96- or 384-well UV plates in a reaction buffer with 50 mM Hepes, pH 7.5, 0.2 mg/ml BSA, 10 mM MgCl2 and 2 mM DTT. Experimental data were fitted with a cooperative equation obtaining a Ks* of about 60 μM and a Hill coefficient (n) of 2.0 ± 0.1.The HTS campaign was performed against a 1-million-compound library using a miniaturized assay in 1,536-well format and a more sensitive ADP detection system, Transcreener ADP FP. A 20-min preincubation of 10 nM VCP and 10 μM inhibitor was performed, after which 10 μM ATP was added to the reaction, which was allowed to proceed for 90 min before quenching. The average Z′ of the screening was 0.58, and the hit rate using 3× s.d. (38% inhibition) as cutoff was 1.7%. Primary hits with >60% inhibition at 10-μM concentration were pruned using physicochemical and structural filters to leave 7,516 compounds. At the end, reconfirmation was performed in duplicate on 3,988 primary hits, and 500 compounds were selected for a dose-response evaluation using the previously described NADH-modified coupled assay.The potency of the most interesting HTS hits was measured against both wild-type VCP and the C522T mutant. ATP concentrations that yielded the half-maximal velocity (Ks*) for each enzyme, corresponding to 60 μM and 130 μM for the wild type and C522T mutant, respectively, were used in the assay. To explore the dependency of reversible inhibitors from substrate concentration, their potency was evaluated also at saturating ATP concentration (1 mM) and compared to the potency of a standard ATP competitive inhibitor (AMP-PNP). |
Cell experiment [1]: | |
Cell lines |
HCT116, HeLa cells |
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
0.5, 2.5 μM for 6h |
Applications |
NMS-873 activated the unfolded protein response, interfered with autophagy and induced cancer cell death. NMS-873 mediated stabilization of Mcl-1 in live cells. NMS-873 inhibited the proliferative activity in HCT116 and HeLa cells with IC50 values of 0.4 and 0.7 μM, respectively. |
References: 1Magnaghi, P., D'Alessio, R., Valsasina, B., Avanzi, N., Rizzi, S., Asa, D., Gasparri, F., Cozzi, L., Cucchi, U., Orrenius, C., Polucci, P., Ballinari, D., Perrera, C., Leone, A., Cervi, G., Casale, E., Xiao, Y., Wong, C., Anderson, D. J., Galvani, A., Donati, D., O'Brien, T., Jackson, P. K. and Isacchi, A. (2013) Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol. 9, 548-556 |
Cas No. | 1418013-75-8 | SDF | |
同義語 | VCP Inhibitor III | ||
Chemical Name | 3-[3-cyclopentylsulfanyl-5-[[3-methyl-4-(4-methylsulfonylphenyl)phenoxy]methyl]-1,2,4-triazol-4-yl]pyridine | ||
Canonical SMILES | CC1=C(C=CC(=C1)OCC2=NN=C(N2C3=CN=CC=C3)SC4CCCC4)C5=CC=C(C=C5)S(=O)(=O)C | ||
Formula | C27H28N4O3S2 | M.Wt | 520.67 |
溶解度 | ≥ 17.1mg/mL in DMSO | Storage | Store at -20° C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 1.9206 mL | 9.603 mL | 19.206 mL |
5 mM | 0.3841 mL | 1.9206 mL | 3.8412 mL |
10 mM | 0.1921 mL | 0.9603 mL | 1.9206 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 22 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *